Preliminary observations using HTV-specific transfer factor in AIDS

Biotherapy

Volumn 9, Issue 1-3, 1996, Pages 41-47

  Pizza, Giancarlo ^a   Chiodo, Francesco ^a   Colangeli, Vincenzo ^a   Gritti, Francesco ^b   Raise, Enzo ^a   Fudenberg, Hugh H ^c   De Vinci, Caterina ^d   Viza, Dimitri ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c Neuro Immuno Therapeutics Found   (United States)

^d CNRS   (France)

Author keywords

AIDS; CDS; Cell mediated immunity; Cytotoxic t lymphocytes; HIV; Transfer factor

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; LAMIVUDINE; TRANSFER FACTOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CLONAL ANERGY; CONFERENCE PAPER; DELAYED HYPERSENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV; HUMANS; MALE; MICE; MICE, INBRED BALB C; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTE SUBSETS; TRANSFER FACTOR;

EID: 0029772092     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02628655     Document Type: Article

References (28)

1. Steele RW, Myers MG & Vincent MM. Transfer factor for the prevention of varicella zoster infection in childhood leukemia. New Engl 1 Med 1980; 303: 355-359.
2. Viza D, Rosenfeld F, Phillips J, Vich JM, Denis J, Bonissent JF, Dogbe K. Specific bovine transfer factor for the treatment of herpes infections. In: Kirkpatrick CH, Burger DR, Lawrence HS, eds. Immunobiology of transfer factor. New York: Academic Press, 1983; 245-259.
3. Dwyer JM: The use of antigen specific transfer factor in the management of infections with herpes viruses. In: Immunobiology of Transfer Factor. Eds. Kirkpatrick CH, Burger DR & Lawrence HS. New York: Academic Press, 1983: 233-42.
4. Viza D, Vich JM, Phillips J, Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985; 4: 27-30.
5. Viza D, Vich JM, Phillips J, Rosenfeld F, Davies DAL. Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555-62.
6. Roda E, Viza D, Pizza G, Mastroroberto L, Phillips J, De Vinci C & Barbara L. Transfer factor for the treatment of HBsAgpositive chronic active hepatitis. P Soc Exp Med 1985; 178: 468-475.
7. Neequaye J, Viza D, Pizza G, Levine PH, De Vmci C, Ablashi DV, Biggar RJ & Nkrumah FK. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma. Anticanc R 1990; 10: 1 ISSUS?.
8. Nkrumah F, Pizza G, Viza D, Phillips J, De Vinci C & Levine P. Regression of progressive lymphadenopathy in a young child with acute cytomegalovirus (CMV) infection following the administration of transfer factor with specific anti-CMV activity. Lymphok Res 1985; 4: 237-241.
9. Viza D., Lefesvre A., Patrasco M., Phillips J.,Hebbrecht N., Laumond G., Vich J.M. A preliminary report on three AIDS patients treated with anti-HIV specific transfer factor. J Exp Path 1987; 3: 653-659.
10. Carey J, Lederman M, Toosi Z, Edmonds K, Hodder S, Calatrese L, Proffitt M, Johnson C, Ellner J. Augmentation of skin test reactivity and lymphocyte blastogenesis in patients with AIDS treated with Transfer Factor, JAMA 1987; 257:651-55.
11. Popovic M, Sarngadharan MG, Read E & Gallo RC. Detection isolation and continuous production of cytopathic human T-lymphotrophic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224:497-500.
12. Viza D, Boucheix Cl, Césarini JP, Ablashi DV, Armstrong G, Levine PH, Pizza G. Characterization of a human lymphoblastoid cell line, LDV/7, used to replicate transfer factor and immune RNA. Bio Cell 1982; 46: 1-10.
13. Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A, Mueller-Bérat N. In vitro production of transfer factor by lymphoblastoid cell lines. Transplan P 1975; VII (suppl. 1): 32933.
14. S0berg M, Bendixen G. Human lymphocyte migration as a parameter of hypersensitivity. Acta Med Scand 1967; 181: 247-53.
15. Centifanto YP, Zam ZS, McNeil JL, Kaufman HE. Leukocytes migration inhibitory factor in HSV infections. Invest Ophtalm Vis Sei 1978; 17: 863-68.
16. Ross CE, Cochran AJ, Hoyle DE, Grant RM, Mackie RM. Formalin-fixed tumour cells in the leukocytes migration test. Lancet, 1973; ii, 1087.
17. Gottlieb MS, Zackin RA, Fiala M, Henry DH, Marcel AJ, Combs KL, Vieira J, Liebman HA, Cone LA, Hillman KS & Gotdieb AA. Response to treatment with the leukocytederived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex: A multicanter, doubleblind, placebo-controlled trial. AnnlntMed 1991; 115: 84-91.
18. Gottlieb AA, Sizemore RC, Gottlieb MS & Kern CH. Rationale and clinical results of using leucocyte-derived irnmunosupportive therapies in HIV disease. Biotherapy, this issue.
19. Dolan MJ, Clerici M, Blatt SP, Hendrix CW, Melcher GP, Boswell RN, Freeman TM, Ward W, Hensley R & Shearer GM. In vitro T il function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995; 172: 79-87.
20. Fernandez-Ortega C, Dubed M, Ruibal O, Vilarrubia OL, Menéndez de San Pedro JC, Navea L, Ojeda M & Arafia MJ. Inhibition of in vitro HTV infection by dialysable leucocyte extracts. Biotherapy, this issue.
21. Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V & Baricordi V. Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses. Biotherapy, this issue.
22. Viza D. "The AIDS panic" Nature 1985; 317 ; 281.
23. Auger I, Thomas P & DeGruttola V. Incubation periods for pédiatrie AIDS patients. Nature 1988; 336: 575-77.
24. Clerici M, Berzofsky JA, Shearer GM & Tacket CO. Exposure to human immunodeficiency virus type 1 ; specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J Infect Dis 1991; 164:178-82.
25. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho HN, Nishanian PG, Berzofsky JA & Shearer GM. Cellmediated immune response to human immunodeficiency virus (HIV) type l in seronegative homosexual men with recent exposure to HIV-1. J Infect Dis 1992; 156: 1012-19.
26. Viza D. AIDS and Transfer Factor: Myths, Certainties and Realities. Biotherapy, this issue.
27. Barrow P, Lewicki H, Hahn BH, Shaw GM & Oldstone MBA. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-10.
28. Rowland-Jones A, Sutton J, Ariyoshi K, Dont T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takaguchi M, Schulte T, McMichael A & Whittle H. HIVspecific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Medicine 1995; 1: 59-64.